Statements (19)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:biotechnology
|
| gptkbp:CEO |
gptkb:Andrew_Cheng
|
| gptkbp:clinicalTrialPhase |
Phase 2b (as of 2023, for efruxifermin)
|
| gptkbp:developedBy |
gptkb:efruxifermin
|
| gptkbp:focusesOn |
gptkb:nonalcoholic_steatohepatitis_(NASH)
|
| gptkbp:foundedYear |
2017
|
| gptkbp:founder |
gptkb:Andrew_Cheng
|
| gptkbp:hasCompany |
true
|
| gptkbp:headquartersLocation |
gptkb:South_San_Francisco,_California,_United_States
|
| https://www.w3.org/2000/01/rdf-schema#label |
Akero Therapeutics
|
| gptkbp:industry |
gptkb:biotechnology
|
| gptkbp:listedOn |
gptkb:NASDAQ
|
| gptkbp:numberOfEmployees |
approximately 50-100 (as of 2023)
|
| gptkbp:specializesIn |
therapies for metabolic diseases
|
| gptkbp:stockSymbol |
gptkb:AKRO
gptkb:NASDAQ |
| gptkbp:website |
https://www.akerotx.com/
|
| gptkbp:bfsParent |
gptkb:Apple_Tree_Partners
|
| gptkbp:bfsLayer |
6
|